Improving outcomes in gastric cancer over 20 years

被引：71

作者：

Desai A.M. ^{[1
]}

Pareek M. ^{[2
]}

Nightingale P.G. ^{[3
]}

Fielding J.W.L. ^{[1
]}

机构：

[1] Department of Surgery, Queen Elizabeth Hospital

[2] Department of Medicine, City Hospital, Birmingham

[3] Wolfson Computer Laboratory, University of Birmingham, Birmingham

来源：

Gastric Cancer | 2004年 / 7卷 / 4期

关键词：

Gastric cancer; Lymphadenectomy; Sentinel lymph node; Surgery; Survival;

D O I：

10.1007/s10120-004-0289-0

中图分类号：

学科分类号：

摘要：

Background. Gastric cancer has in the past proven to be a difficult disease to cure. Surgery is the most effective treatment, although the extent of lymphadenectomy undertaken is controversial. This paper examines trends in the detection and treatment of gastric cancer, the move toward targeted surgery, and their impact on survival. Methods. From 1982 to 2001, 430 patients with gastric cancer were under the care of a single surgeon at the same institution. Copies of the operation records, discharge summaries, and histology reports were retained and subsequently reviewed. Results. Thirty-six patients were excluded from the analysis. Two hundred and five patients (52%) had potentially curative surgery for adenocarcinoma and 189 had incurable disease. During the 20-year period, overall 5-year survival increased significantly, from 15% to 41% (P < 0.01). The number of curative procedures also increased significantly, from 33% to 73% (P1 < 0.001) as disease was detected earlier, and 5-year survival in these patients increased from 26% to 46%. Eighty-seven D1, 92 D2, and 26 targeted procedures were performed, with 30-day mortalities of 5%, 9%, and 5%, respectively. The 5-year survival was 47% for D1, 42% for D2, and 66% for targeted surgery. Conclusion. This paper demonstrates an improvement in the stage at which disease was detected and improvement in long-term survival for patients with gastric cancer. The development of targeted surgery has shown promising early results.

引用

页码：196 / 201

页数：5

共 25 条

[1]

Allum W.H., Powell D.J., McConkey C.C., Fielding J.W., Gastric cancer: A 25-year review, Br J Surg, 76, pp. 535-540, (1989)

[2]

Earle C.C., Maroun J., Zuraw L., Neoadjuvant or adjuvant therapy for resectable gastric cancer? A practice guideline, Can J Surg, 45, pp. 438-446, (2002)

[3]

Fielding J.W., Fagg S.L., Jones B.G., Ellis D., Hockey M.S., Minawa A., Et al., An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer: British Stomach Cancer Group, World J Surg, 7, pp. 390-399, (1983)

[4]

Hallissey M.T., Dunn J.A., Ward L.C., Allum W.H., The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: 5-Year follow-up, Lancet, 343, pp. 1309-1312, (1994)

[5]

Hermans J., Bonenkamp J.J., Boon M.C., Bunt A.M., Ohyama S., Sasako M., Et al., Adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomized trials, J Clin Oncol, 11, pp. 1441-1447, (1993)

[6]

Langman M.J., Dunn J.A., Whiting J.L., Burton A., Hallissey M.T., Fielding J.W., Et al., Prospective, double-blind, placebo-controlled randomized trial of cimetidine in gastric cancer, Br J Cancer, 81, pp. 1356-1362, (1999)

[7]

Mackay H.J., McInnes A., Paul J., Raby N., Lofts F.J., Mc Donald A.C., Et al., A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma, Ann Oncol, 12, pp. 1407-1410, (2001)

[8]

Allum W.H., Hallissey M.T., Kelly K.A., Adjuvant chemotherapy in operable gastric cancer. Five-year follow-up of first British Stomach Cancer Group trial, Lancet, 1, pp. 571-574, (1989)

[9]

Hundahl S.A., Stemmermann G.N., Oishi A., Racial factors cannot explain superior Japanese outcomes in stomach cancer, Arch Surg, 131, pp. 170-175, (1996)

[10]

Maruyama K., Okabayashi K., Kinoshita T., Progress in gastric cancer surgery in Japan and its limits of radicality, World J Surg, 11, pp. 418-425, (1987)

← 1 2 3 →